Chief Scientific Officer, PolyProx Therapeutics
Prof Itzhaki has 25 years’ experience leading academic research in the field of protein engineering and is a Professor in the Department of Pharmacology at the University of Cambridge. Prof Itzhaki is scientific co-Founder and CSO of PolyProx Therapeutics, a biotechnology company focused on the discovery and development of a new class of drugs, Polyproxin® molecules, to treat cancer and neuro-degenerative diseases. Polyproxin molecules are biopharmaceuticals that selectively target disease-causing proteins and use natural cellular pathways to destroy them.
16 November 2020
BOOK YOUR PLACE NOW